Story perspectives

FDA Greenlights Second Generic Mifepristone Amid Safety Concerns

10/23/2025

29 6

Summary

Story summary

The FDA approved a second generic version of mifepristone, increasing competition and access.
Critics, including Republican attorneys general, say the decision, under U.S. President Donald Trump, raises safety concerns.
They contend the approval disregards risks, noting significantly higher adverse events than previously reported.
Supporters view the move as boosting competition and access.
The decision has intensified scrutiny of the administration’s abortion-access policy.

1 of 1

Story summary

The FDA approved a second generic version of mifepristone, increasing competition and access.
Critics, including Republican attorneys general, say the decision, under U.S. President Donald Trump, raises safety concerns.
They contend the approval disregards risks, noting significantly higher adverse events than previously reported.
Supporters view the move as boosting competition and access.
The decision has intensified scrutiny of the administration’s abortion-access policy.